Can Cellceutix (CTIX.OB) Chief Scientific Officer Repeat History with Cancer Drug?

Many scientists never get to taste the success of developing a successful compound. With over 1,000 biotechnology companies in North America presently, there are thousands of researchers that are working every day to develop drugs with one goal in mind: FDA approval. There are more than 2,000 drugs in development at this time. Estimates vary, but only 5 to 10 percent of compounds ever make it to this final goal. How rare is FDA approval for a new drug? In the last three years, 65 new drugs have been granted final FDA clearance (25 in 2009, 22 in 2008 and 18 in 2007).

Dr. Krishna Menon, Chief Scientific Officer of Cellceutix Corporation has been involved in the development of a successful compound not once, but twice. While a lead researcher at Eli Lilly and Company (NYSE:LLY), Dr. Menon was integral to the initial research on cancer drugs Pemetrexed (marketed as “Alimta”) and Gemcitabine (marketed as “Gemzar”).

Granted its first FDA approval in August of 2004, Alimta is a chemotherapy drug used to treat non-small cell lung cancers and mesothelioma, a form of lung cancer associated with the exposure to asbestos. Alimta has received 4 different FDA approvals as a therapy for cancers with the most recent coming in July of last year.

Gemzar received FDA approval in July of 2006 as a therapy to be used in combination with carboplatin for patients with advanced ovarian cancer that have suffered a relapse after receiving treatments of platinum-based therapies. Presently, it is also used to treat cancers of the pancreas, lung and breast.

These two drugs combined are responsible for billions of dollars annually for Eli Lilly. Gemzar has revenues totaled $1.59 billion in 2007, $1.71 billion in 2008 and $1.36 billion in 2009. Total revenues from Alimta were $854 million in 2007, $1.52 billion in 2008 and $1.71 billion in 2009. That’s nearly $9 billion in combined revenues of the last three years.

As CSO at Cellceutix, Dr. Menon is presently working on developing another novel compound for the treatment of cancer. Kevetrin™, the Company’s flagship compound, is approaching Phase I clinical trials as a therapy for specific strains of multi-drug resistant cancers of the lungs, colon and breast. Pre-clinical research is nearly completed as Cellceutix is only awaiting final data from toxicology studies which is anticipated within the next two weeks. Cellceutix is making preparations for an Investigational New Drug (IND) filing with the FDA and human trials will follow (tentatively scheduled for late fourth quarter 2010 or early first quarter 2011).

The pre-clinical data collected has been very promising for Kevetrin as detailed by Cellceutix throughout via press releases and website ( In a recent press release, Dr. Menon stated, “I have been closely involved in the development of several successful compounds in my 30 years in the industry and am extremely encouraged by the data that Kevetrin has produced.” If Dr. Menon is encouraged by the data collected thus far, it leads to the question “Is he going to do it again?”

More information on Cellceutix Corporation, Kevetrin for multi-drug resistant cancers and the investment opportunity presented can be found on the Company’s website at


Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

MEDL Mobile Partner DJ Pauly D Nominated for Best App Ever Award $MEDL(0)

Mobile app developer MEDL Mobile, Inc. (OTCBB:MEDL) reported that partner DJ Pauly D’s app “Beat That Boardwalk” has been nominated for the 2011 Best Music Game for Android at The Best App Ever Awards ( by the popular app review site. MEDL Mobile Co-Founder Dave Swartz said, “We wanted to do something unexpected for DJ

NexCore Healthcare Capital Leading Percentage Gainers on the OTCBB Today $NXHC(0)

With one hour remaining before today’s closing bell, a look at today’s percentage gainers on the Over the Counter Bulletin Board: NexCore Healthcare Capital Corp. (OTCBB:NXHC) is up 483.09% to $0.20 on 9.1k in volume China Advanced Technology (OTCBB:CADT) is up 234.71% to $4.05 on 300k in volume AISYSTEMS, Inc. (OTCBB:ASYI) is up 147.06% to

Platinum Studios and Mark Canton Partner for “Atlantis Rising” Film Series $PDOS(0)

Platinum Studios Inc. (OTCBB:PDOS) and producer/Platinum Studios Board Member Mark Canton announced that they will be teaming-up to immediately begin work on bringing the Platinum Studios comic book “Atlantis Rising” into an ongoing franchise for the silver screen.  The film is set against an undersea civilization that began over 10,000 years ago, and whose presence

Cannabis Science Updates Show Cannabis Extracts Killing Skin Cancer $CBIS(0)

Following news in December 2011 of a second cancer patient self-administering cannabis extract to combat basal cell carcinoma (skin cancer), Cannabis Science, Inc. (OTCBB:CBIS) reported today that it appears that the cannabis therapy has eradicated the cancer.  The company stated that they are waiting for a full biopsy report to confirm that the cancer is

Bebida Beverage Bringing Koma Unwind to New York City $BBDA(0)

Relaxation Drink “Koma Unwind” will be available to people in the New York City area, according to manufacturer Bebida Beverage Company (Pink Sheets:BBDA).  The company reported this morning that it has signed new agreements with S.K.I. Beer and All Star Imports to distribute the non-alcoholic drink throughout the NYC vicinity. S.K.I. will be rolling-out Koma

read more

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.